240 related articles for article (PubMed ID: 37500124)
1. Prognostic Value of TACE With Irinotecan-loaded Drug-eluting Beads (DEBIRI) in Patients With Liver Metastases from Unresectable Colorectal Cancer.
Ishikawa T; Imai M; Sato R; Jimbo R; Kobayashi Y; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
Anticancer Res; 2023 Aug; 43(8):3647-3651. PubMed ID: 37500124
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for overall survival and safety of trans-arterial chemoembolization (TACE) with irinotecan-loaded drug-eluting beads (DEBIRI) in patients with colorectal liver metastases.
Sljivic M; Sever M; Ocvirk J; Mesti T; Brecelj E; Popovic P
Radiol Oncol; 2024 Jun; 58(2):214-220. PubMed ID: 38553252
[TBL] [Abstract][Full Text] [Related]
3. Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer.
Narayanan G; Barbery K; Suthar R; Guerrero G; Arora G
Anticancer Res; 2013 May; 33(5):2077-83. PubMed ID: 23645758
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases.
Bhutiani N; Akinwande O; Martin RC
World J Surg; 2016 May; 40(5):1178-90. PubMed ID: 26711640
[TBL] [Abstract][Full Text] [Related]
5. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review.
Richardson AJ; Laurence JM; Lam VW
J Vasc Interv Radiol; 2013 Aug; 24(8):1209-17. PubMed ID: 23885916
[TBL] [Abstract][Full Text] [Related]
6. Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes.
Voizard N; Ni T; Kiss A; Pugash R; Raphael MJ; Coburn N; David E
Curr Oncol; 2022 Jan; 29(1):209-220. PubMed ID: 35049694
[TBL] [Abstract][Full Text] [Related]
7. Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report.
Martin RC; Robbins K; Tomalty D; O'Hara R; Bosnjakovic P; Padr R; Rocek M; Slauf F; Scupchenko A; Tatum C
World J Surg Oncol; 2009 Nov; 7():80. PubMed ID: 19886993
[TBL] [Abstract][Full Text] [Related]
8. Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial.
Pernot S; Artru P; Mithieux F; Marsot J; Watkin E; Pellerin O; Lledo G; Chalabreysse P; Desramé J; Taieb J
Clin Res Hepatol Gastroenterol; 2015 Dec; 39(6):e73-7. PubMed ID: 26141343
[TBL] [Abstract][Full Text] [Related]
9. The power of genes: a case of unusually severe systemic toxicity after localized hepatic chemoembolization with irinotecan-eluted microspheres for metastatic colon cancer.
Cruz JE; Saksena R; Jabbour SK; Nosher JL; Hermes-DeSantis E; Moss RA
Ann Pharmacother; 2014 Dec; 48(12):1646-50. PubMed ID: 25202035
[TBL] [Abstract][Full Text] [Related]
10. Chemoembolization with drug eluting beads preloaded with irinotecan (DEBIRI) vs doxorubicin (DEBDOX) as a second line treatment for liver metastases from cholangiocarcinoma: a preliminary study.
Venturini M; Sallemi C; Agostini G; Marra P; Cereda S; Reni M; Aldrighetti L; De Cobelli F; Del Maschio A
Br J Radiol; 2016 Nov; 89(1067):20160247. PubMed ID: 27558984
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan eluting beads-transarterial chemoembolization using Callispheres® microspheres is an effective and safe approach in treating unresectable colorectal cancer liver metastases.
Zhao G; Liu S; Zhang Y; Zhao T; Wang R; Bian J; Wu J; Zhou J
Ir J Med Sci; 2022 Jun; 191(3):1139-1145. PubMed ID: 34264426
[TBL] [Abstract][Full Text] [Related]
12. Drug-eluting beads loaded with irinotecan to treat synchronous liver-only metastases of colorectal cancer non-responsive to bevacizumab-based chemotherapy.
Hsu TF; Chang WC; Chang PY; Lin HH; Chen PK; Ko KH; Chiu SH
Br J Radiol; 2023 Apr; 96(1145):20220767. PubMed ID: 36802795
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial.
Martin RC; Scoggins CR; Tomalty D; Schreeder M; Metzger T; Tatum C; Sharma V
J Gastrointest Surg; 2012 Aug; 16(8):1531-8. PubMed ID: 22528576
[TBL] [Abstract][Full Text] [Related]
14. Transarterial Chemoembolisation of Colorectal Liver Metastases with Irinotecan-Loaded Beads: A Bi-institutional Analysis of 125 Treatments in 53 Patients.
Ngo A; von Stempel C; Corbo B; Bandula S; Shiu KK; Raja J; Hague J; Evans J; Kibrya N
Cardiovasc Intervent Radiol; 2019 Jul; 42(7):979-990. PubMed ID: 31044294
[TBL] [Abstract][Full Text] [Related]
15. Does Bead Size Affect Patient Outcome in Irinotecan-Loaded Beads Chemoembolization Plus Systemic Chemotherapy Regimens for Liver-Dominant Colorectal Cancer? Results of an Observational Study.
Boeken T; Moussa N; Pernot S; Abed A; Dean C; Taieb J; Sapoval M; Pellerin O
Cardiovasc Intervent Radiol; 2020 Jun; 43(6):866-874. PubMed ID: 32103303
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM
Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602
[TBL] [Abstract][Full Text] [Related]
17. Early Experience with 70-150 μm Irinotecan Drug-eluting Beads (M1-DEBIRI) for the Treatment of Unresectable Hepatic Colorectal Metastases.
Akinwande O; Scoggins C; Martin RC
Anticancer Res; 2016 Jul; 36(7):3413-8. PubMed ID: 27354601
[TBL] [Abstract][Full Text] [Related]
18. Radiological assessment of response to neoadjuvant transcatheter hepatic therapy with irinotecan-eluting beads (DEBIRI(®)) for colorectal liver metastases does not predict tumour destruction or long-term outcome.
Jones RP; Stättner S; Dunne DF; O'Grady E; Smethurst A; Terlizzo M; Malik HZ; Fenwick SW; Poston GJ
Eur J Surg Oncol; 2013 Oct; 39(10):1122-8. PubMed ID: 23928482
[TBL] [Abstract][Full Text] [Related]
19. Review of the Clinical Evidence for the Use of DEBIRI in the Treatment of Colorectal Metastatic Disease.
Young S; D'Souza D; Flanagan S; Golzarian J
Cardiovasc Intervent Radiol; 2017 Apr; 40(4):496-501. PubMed ID: 28004168
[TBL] [Abstract][Full Text] [Related]
20. PARAGON II - A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer.
Jones RP; Malik HZ; Fenwick SW; Terlizzo M; O'Grady E; Stremitzer S; Gruenberger T; Rees M; Plant G; Figueras J; Albiol M; Adam R; Awad S; Poston GJ
Eur J Surg Oncol; 2016 Dec; 42(12):1866-1872. PubMed ID: 27561844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
